Specifica, a privately held antibody engineering company focused on innovative in vitro antibody libraries and discovery tools, has reached an agreement with the global healthcare company Sanofi.
In this agreement, Specifica’s Generation 3 Antibody Discovery Platform will be transferred to Sanofi. This will enable the integration of Specifica’s Gen 3 platform into Sanofi’s antibody discovery programs.
What does this platform do? Specifica’s Gen 3 libraries combine clinically validated antibody frameworks with compatible binding loop sequences from natural human antibodies that have been purged of sequence-based developability liabilities.
Specifica CEO Ken Sharples has said that the partnership with Sanofi will provide a “complete antibody discovery platform through a combination of Gen 3 libraries, antibody optimization solutions, and integrated discovery tools.”
Specifica is a start up company in New Mexico that was originally supported by the New Mexico Consortium.
Read more on Specifica’s news page at: https://www.specifica.bio/specifica-announces-antibody-discovery-platform-transfer-agreement-with-sanofi/